Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Dec 1;56(12):2093-2101.
doi: 10.1093/rheumatology/kex269.

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

Paul Emery  1   2 , Jirí Vencovský  3 , Anna Sylwestrzak  4 , Piotr Leszczynski  5 , Wieslawa Porawska  6 , Asta Baranauskaite  7 , Vira Tseluyko  8 , Vyacheslav M Zhdan  9 , Barbara Stasiuk  10 , Roma Milasiene  11 , Aaron Alejandro Barrera Rodriguez  12 , Soo Yeon Cheong  13 , Jeehoon Ghil  13
Affiliations
Clinical Trial

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

Paul Emery et al. Rheumatology (Oxford). .

Abstract

Objective: To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA.

Methods: In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA despite MTX treatment were randomized to receive 50 mg/week of s.c. SB4 or ETN up to week 52. Efficacy assessments included ACR response rates, 28-joint DAS, Simplified and Clinical Disease Activity Indices and changes in the modified total Sharp score (mTSS). Safety and immunogenicity were also evaluated.

Results: A total of 596 patients were randomized to receive either SB4 (n = 299) or ETN (n = 297) and 505 (84.7%) patients completed 52 weeks of the study. At week 52, the ACR20 response rates in the per-protocol set were comparable between SB4 (80.8%) and ETN (81.5%). All efficacy results were comparable between the two groups and they were maintained up to week 52. Radiographic progression was also comparable and the change from baseline in the mTSS was 0.45 for SB4 and 0.74 for ETN. The safety profile of SB4 was similar to that of ETN and the incidence of anti-drug antibody development up to week 52 was 1.0 and 13.2% in the SB4 and ETN groups, respectively.

Conclusion: Efficacy including radiographic progression was comparable between SB4 and ETN up to week 52. SB4 was well tolerated and had a similar safety profile to that of ETN.

Trial registration number: ClinicalTrials.gov NCT01895309, EudraCT 2012-005026-30.

Keywords: Benepali; SB4; biologics; biosimilar; etanercept; rheumatoid arthritis.

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Summary of patient disposition Among the patients who withdrew under investigator discretion, 13 patients in the SB4 group and 8 patients in the ETN group were withdrawn due to the political crisis in Ukraine. ETN: reference etanercept.
<sc>Fig</sc>. 2
Fig. 2
ACR response rates up to week 52 (full analysis set) ETN: reference etanercept.
<sc>Fig</sc>. 3
Fig. 3
Change in mTSS at week 52 ETN: reference etanercept.
See this image and copyright information in PMC

References

    1. Kuek A, Hazleman BL, Ostor AJ.. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251–60. - PMC - PubMed
    1. Curtis JR, Singh JA.. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011;33:679–707. - PMC - PubMed
    1. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther 2011;13:112. - PMC - PubMed
    1. Ruff L, Rezk MF, Uhlig T, Gommers JW.. Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis in Europe. Value Health 2015;18:A639.
    1. Lee YJ, Shin D, Kim Y. et al. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. Br J Clin Pharmacol 2016;82:64–73. - PMC - PubMed

Publication types

Associated data